Coave Therapeutics Demonstrates its Modified coAAV Vectors Outperform AAV9 to Address Neurological Disorders New data to be presented at ASGCT 2023 Paris, France, May 4, 2023 - Coave Therapeutics (‘Coave’), a clinical-stage biotechnology company focused on developing life-changing gene therapies for CNS...

Coave Therapeutics to Present at Upcoming Conferences Paris, France, March 16, 2023 - Coave Therapeutics (‘Coave’), a clinical-stage biotechnology company focused on developing life-changing gene therapies for CNS (Central Nervous System) and eye...